Tests SB17170 against placebo in people with idiopathic pulmonary fibrosis
Tests SB17170 or placebo for 12 weeks in adults with moderate to severe lung scarring.
Plain-language title generated from the registry record
Registry title: SB17170 Phase 2 Trial in IPF Patients
Key facts
- Where
- Goyang, Gwangmyeong, Seoul, and Suwon, South KoreaSee the 5 sites
- Phase
- Phase 2
Where in South Korea
- Myong Ji HospitalGoyang, South KoreaTaking people
- Chung-Ang University Gwangmyeong HospitalGwangmyeong, South KoreaTaking people
- Seoul Asan HospitalSeoul, South KoreaNot yet recruiting
- The Catholic Univ. of Korea Seoul St. Mary's HospitalSeoul, South KoreaNot yet recruiting
- Ajou University HospitalSuwon, South KoreaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- SPARK Biopharma
- Trial code
- NCT06747923
- Record updated
- 19 November 2025
- Original description
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
Inclusion: Adult male/female 40 years or older at the time of obtaining informed consent; Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria:; Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan; Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit; Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria; Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit; Patients meeting pulmonary function test criteria at the screening visit; Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form.
Exclusion: Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period; Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial; Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product; When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other clinically significant lung abnormalities; Patients with lower respiratory tract infections requiring antibiotic treatment; Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening; Patients with evidence of active infection; Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:; Severe hypertension within 3 months; Myocardial infarction or unstable angina within 6 months; History of thrombotic events within 6 months; Diagnosis of heart failure within 6 months; Patients with pulmonary hypertension; Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C.